Voxelotor (Oxbryta) is the first hemoglobin oxygen-affinity modulator. It has disease-modifying potential by increasing hemoglobin levels and decreasing hemolysis indicators...
Oxbryta
Pfizer has agreed to acquire Global Blood Therapeutics for $5.4 billion. Based on this, Global Blood Therapeutics will hand its...
